Cor Vasa 2018, 60(2):e165-e168 | DOI: 10.1016/j.crvasa.2017.05.011

Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?

Radovan Jirmářa,b,*, Petr Widimskýa
a III. interní klinika-kardiologická, Kardiocentrum 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha, Česká republika
b Kardiologická ambulance, Praha 10, Česká republika

The aim of this review article is to make readers aware of the risk of an inadequate antiplatelet effect of enteric-coated formulations of aspirin. Judging by data from studies published to date and exploring the efficacy of various aspirin formulations, there exist sufficient evidences only of a plain form of aspirin absorbed in the stomach. The implication is that patients with coronary heart disease (CHD) should be treated exclusively with the standard formulation of aspirin.

Keywords: Aspirin; Coronary heart disease; Enteric coating; Resistance

Received: March 20, 2017; Accepted: May 17, 2017; Published: April 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirmář R, Widimský P. Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin? Cor Vasa. 2018;60(2):e165-168. doi: 10.1016/j.crvasa.2017.05.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. G. Montalescot, U. Sechtem, S. Achenbach, et al. 2013 ESC guidelines on the management of stable coronary artery disease, European Heart Journal 34 (2013) 2949-3003. Go to original source...
    2. J. Bultas, Antiplatelet therapy - a pharmacologist's perspective, Cor et Vasa 55 (2013) e86-e94. Go to original source...
    3. D.L. Bhatt, T. Grosser, T.J. Dong, et al., Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus, Journal of the American College of Cardiology 69 (2017) 603-612. Go to original source... Go to PubMed...
    4. D. Cox, A.O. Maree, M. Dooley, et al., Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers, Stroke 37 (2006) 2153-2158. Go to original source... Go to PubMed...
    5. T. Grosser, S. Fries, J.A. Lawson, et al., Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin, Circulation 127 (2013) 377-385. Go to original source... Go to PubMed...
    6. A. Maree, R. Curtin, M. Dooley, et al., Platelet response to low dose enteric-coated aspirin in patient with stable cardiovascular disease, Journal of the American College of Cardiology 46 (2005) 1258-1263. Go to original source... Go to PubMed...
    7. M. Roffi, C. Patrono, J.P. Collet, et al., 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal 37 (2016) 267-315. Go to original source... Go to PubMed...
    8. P.G. Steg, S.K. James, D. Atar, et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), European Heart Journal 33 (2012) 2569-2619.
    9. P. Widimský, R. Rokyta, O. Hlinomaz, Summary of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Prepared by the Czech Society of Cardiology, Cor et Vasa 58 (2016) e4-e28. Go to original source...
    10. ISIS-2: a randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Journal of the American College of Cardiology 12 (6 Suppl A) (1988) 3A-13A. Go to PubMed...
    11. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group, Lancet 339 (1992) 753-770.
    12. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, Lancet 336 (1990) 65-71.
    13. The CURERENT OASIS 7 Investigators. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes, New England Journal of Medicine 363 (2010) 930-942.
    14. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial investigators. Effects of clopidogrel in addition to aspirin in patient with acute coronary syndromes without ST-segment elevation, New England Journal of Medicine 345 (2001) 494-502. Go to original source... Go to PubMed...
    15. S.D. Wiviott, E. Braunwald, H.C.H. McCabe, et al., Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 357 (2007) 2001-2015. Go to original source... Go to PubMed...
    16. L. Wallentin, R.C. Becker, A. Budaj, et al., Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine 361 (2009) 1045-1057. Go to original source... Go to PubMed...
    17. Antithrombotic Trialists' (ATT) Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet 373 (2009) 1849-1860. Go to original source...
    18. Collaborative overview of randomised trials of antiplatelet therapy, prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, Antiplatelet Trialists' Collaboration, British Medical Journal 308 (1994) 81-106.
    19. J.P. Kelly, D.W. Kaufman, J.M. Jurgelon, et al., Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product, Lancet 348 (1996) 1413-1416. Go to original source... Go to PubMed...
    20. J. Walker, J. Robinson, J. Stewart, et al., Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin?, Interactive Cardiovascular and Thoracic Surgery 6 (2007) 519-522. Go to original source... Go to PubMed...
    21. V. Fuster, J.M. Sweeny, Aspirin. A Historical and Contemporary Therapeutic Overview, Circulation 123 (2011) 768-778. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes